Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database

BMC Psychiatry

Research Article

Tim Lambert¹  Harry Hustig²  An Jacobs³  Sophie Resseler⁴  Belinda Butcher⁵  Brett Emmerson⁶ 

[1] Department of Psychiatry, The University of Melbourne, Melbourne, Australia;Concord Medical School and Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia;Extended Care Services, Royal Adelaide Hospital, North Terrace Adelaide, SA, Australia;Health Economics & Pricing, Janssen Pharmaceutica, Beerse, Belgium;Life Science Services--Biometrics, SGS, Antwerp, Belgium;Medical Research, Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia;WriteSource Medical Pty Ltd, Lane Cove, NSW, Australia;Mental Health Services, Royal Brisbane and Women's Hospital, Herston, QLD, Australia;

关键词: Schizophrenia;    Clozapine;    Risperidone;    Schizoaffective Disorder;    Psychiatric Medication;   

DOI  :  10.1186/1471-244X-12-25

 received in 2011-07-13, accepted in 2012-03-26,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundThis observational study was designed to collect treatment outcomes data in patients using the electronic Schizophrenia Treatment Adherence Registry (e-STAR).MethodsPatients with schizophrenia or schizoaffective disorder in Australia who were prescribed risperidone long-acting injection (RLAI) between 2003 and 2007 were assessed 12-months retrospectively, at baseline and 24-months prospectively at 3-monthly intervals. The intent-to-treat population, defined as all patients who received at least one dose of RLAI at baseline, was used for the efficacy and safety analyses.ResultsAt total of 784 patients (74% with schizophrenia, 69.8% male) with a mean age of 37.1 ± 12.5 years and 10.6 ± 9.5 years since diagnosis were included in this Australian cohort. A significant improvement in mean Clinical Global Impression - severity score was observed at 24-months (4.52 ± 1.04 at baseline, 3.56 ± 1.10 at 24-months). Most of this improvement was seen by 3-months and was also reflected in mean Global Assessment of Functioning score, which improved significantly at 24-months (42.9 ± 14.5 at baseline, 59 ± 15.4 at 24-months). For patients still receiving RLAI at 24-months there was an increase from a mean baseline RLAI dose of 26.4 ± 5 mg to 43.4 ± 15.7 mg. Sixty-six percent of patients discontinued RLAI before the 24-month period--this decreased to 46% once patients lost to follow-up were excluded.ConclusionOver the 24-month period, initiation of RLAI was associated with improved patient functioning and illness severity in patients with schizophrenia or schizoaffective disorder. Improved outcomes were observed early and sustained throughout the study.Trial RegistrationClinical Trials Registration Number, NCT00283517.

【 授权许可】

CC BY   
© Lambert et al; licensee BioMed Central Ltd. 2012